Repurposing GLP-1 Receptor Agonists for Parkinsons Disease: Current Evidence and Future Opportunities
GLP-1 Drug Biosimilar Market Report Scope: Market Segmentation: GLP-1 Drug Biosimilar Market by Reference Biologic - Semaglutide Biosimilar Liraglutide Biosimilar Exenatide Biosimilar Dulaglutide Biosimilar GLP-1 Drug Biosimilar Market by Formulation - Injectable Pen Oral Tablet Patch & Implant GLP-1 Drug Biosimilar Market by Distribution - Retail Pharmacy Mail-Order & Specialty Pharmacy Hospital & Clinic By Region- North America- The US Canada Europe - Germany The UK France Italy Spain Rest of Europe Asia-Pacific- China Japan India South Korea South East Asia Rest of Asia Pacific Latin America- Brazil Argentina Mexico Rest of Latin America Middle East & Africa- GCC Countries South Africa Rest of Middle East and Africa Research Design and Approach This study employed a multi-step, mixed-method research approach that integrates: Secondary research Primary research Data triangulation Hybrid top-down and bottom-up modelling Forecasting and scenario analysis This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market
In conjunction with a healthy diet, metabolic optimization through the use of 5-Amino-1MQ could contribute to increased longevity, decreased weight gain, and improved overall health
(2023), New England Journal of Medicine 389(6), DOI 10.1056/NEJMoa2301972 Statistics from clinical literature Developer: Eli Lilly and Company , code name LY3437943 Mechanism: triple agonist acting at GLP-1 , GIP and glucagon receptors, the first such peptide in advanced clinical development Phase 2 obesity trial (NEJM 2023) results at 12 mg/week dose, n=338: 24.2 % mean reduction in body weight at 48 weeks 25.8 % loss of body fat (DEXA) 9.7 % reduction in hemoglobin A1c in prediabetic patients Phase 2 type 2 diabetes trial (Lancet 2023): 2.02 % point A1c reduction at 36 weeks vs
So enjoy
